Evotec today announced that its partner STORM Therapeutics Ltd. (“STORM”), a clinical stage biotechnology company focused on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, will be presenting the discovery of its lead clinical candidate, STC-15, at the American Chemical Society (ACS) Fall 2023 Conference. STC-15, an orally bioavailable and highly selective METTL3 inhibitor, was co-designed and developed through a collaboration between STORM and Evotec. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-partner-storm-therapeutics-to-present-the-discovery-of-lead-clinical-candidate-stc-15-at-the-american-chemical-society-fall-2023-conference-6318
Evotec provides update on financial impact of cyber-attack
Evotec SE today announced that it is adjusting its guidance for the fiscal year 2023 due to the impact of the cyber-attack. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-provides-update-on-financial-impact-of-cyber-attack-6314
Evotec and Bristol Myers Squibb enter licence agreement within neuroscience partnership
Evotec SE today announced that Bristol Myers Squibb Company has exercised its option to enter into an exclusive global licence agreement. The licence covers selected late-stage discovery programmes that were developed and progressed within the collaboration. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-bristol-myers-squibb-enter-licence-agreement-within-neuroscience-partnership-6312
Just – Evotec Biologics awarded second contract from U.S. Department of Defense under accelerated antibodies program
Evotec SE today announced that the U.S. Department of Defense (“DOD”) has awarded Evotec’s Seattle-based subsidiary, Just – Evotec Biologics, Inc. a contract valued up to $ 74 m for the rapid development of monoclonal antibody (“mAb”)-based drug product prototypes targeting orthopoxviruses. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/just—evotec-biologics-awarded-second-contract-from-us-department-of-defense-under-accelerated-antibodies-program-6310
Evotec receives milestone payment for first patient dosed in Phase I study of Bayer kidney disease programme
Evotec SE announced today that it is to receive a € 2 m milestone payment from Bayer AG, which is triggered by the first patient dosed in the clinical Phase I study of a kidney disease programme stemming from the Evotec-Bayer multi-target research collaboration in kidney diseases. The drug candidate, a monoclonal antibody (“mAb”) targeting the protein Semaphorin-3A (“Sema3A”) is being developed as a potential first-to-market treatment for Alport syndrome, a rare genetic kidney disease. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-milestone-payment-for-first-patient-dosed-in-phase-i-study-of-bayer-kidney-disease-programme-6308
Evotec SE Annual General Meeting 2023 approves all proposed agenda items
Evotec SE today announced that its shareholders approved all proposals the Company’s Management put to vote at the Company’s virtual Annual General Meeting 2023 with the required majority. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-se-annual-general-meeting-2023-approves-all-proposed-agenda-items-6306
Just – Evotec Biologics: Installation of cleanroom PODs at J.POD Toulouse, France (EU)
Evotec SE today announced the successful arrival and start of installation of the cleanroom PODs at its J.POD biologics manufacturing facility located on Evotec’s Campus Curie in Toulouse, France. Manufactured and delivered by G-CON, a global leader in off-site pre-fabricated cleanroom systems, the cleanroom PODs will be installed over the next few weeks. G-CON previously supplied the cleanroom PODs for the first J.POD facility at Just – Evotec Biologics’ site in Redmond, WA (US) in August 2021. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/just—evotec-biologics-installation-of-cleanroom-pods-at-jpod-toulouse-france-eu-6304
Evotec SE to resume dual listing in MDAX and TecDAX
Evotec SE will resume its dual listing in the German stock indices MDAX and TecDAX, following the quarterly index review of the DAX index family through Qontigo, the index operator of Deutsche Börse. The changes were announced by Qontigo after market close on 05 June and will become effective on 19 June 2023. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-se-to-resume-dual-listing-in-mdax-and-tecdax-6302
Evotec presents sustainability strategy
Evotec SE today presents an update on the Company’s sustainability strategy and shares details on its ESG (Environmental, Social and Governance) performance towards strengthening its competitiveness and contributing to a better future for next generations to investors and interested stakeholders at its virtual Capital Markets Day. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-presents-sustainability-strategy-6300
Evotec receives grant from Open Philanthropy for discovery of RNA-targeting Henipavirus therapeutics
Evotec SE today announced that the Company has received a $ 1.7 m grant from Open Philanthropy, a philanthropic funder prioritising global health and wellbeing. Under the grant, Evotec aims to discover and develop RNA-targeting small molecules as potential first-in-class therapeutics against Henipaviruses. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-grant-from-open-philanthropy-for-discovery-of-rna-targeting-henipavirus-therapeutics-6298